NO20063987L - Anti-cancerterapier - Google Patents

Anti-cancerterapier

Info

Publication number
NO20063987L
NO20063987L NO20063987A NO20063987A NO20063987L NO 20063987 L NO20063987 L NO 20063987L NO 20063987 A NO20063987 A NO 20063987A NO 20063987 A NO20063987 A NO 20063987A NO 20063987 L NO20063987 L NO 20063987L
Authority
NO
Norway
Prior art keywords
cancer therapies
odds
treating
procedures
disclosed
Prior art date
Application number
NO20063987A
Other languages
English (en)
Other versions
NO336884B1 (no
Inventor
George Tidmarsh
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of NO20063987L publication Critical patent/NO20063987L/no
Publication of NO336884B1 publication Critical patent/NO336884B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Det er beskrevet fremgangsmåter for behandling av kanser. Spesielt er det beskrevet fremgangsmåter for behandling av kanser omfattende administrering av glufosfamid alene eller i kombinasjon med et annet antikansermiddel.
NO20063987A 2004-02-06 2006-09-06 Glufosfamid og gemcitabin for behandling av kanser, og glufosfamid for behandling av kjemoterapi-motstandsdyktig bukspyttkjertelkanser. NO336884B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54249404P 2004-02-06 2004-02-06
PCT/US2005/003370 WO2005076888A2 (en) 2004-02-06 2005-02-04 Anti-cancer therapies

Publications (2)

Publication Number Publication Date
NO20063987L true NO20063987L (no) 2006-09-06
NO336884B1 NO336884B1 (no) 2015-11-23

Family

ID=34860311

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063987A NO336884B1 (no) 2004-02-06 2006-09-06 Glufosfamid og gemcitabin for behandling av kanser, og glufosfamid for behandling av kjemoterapi-motstandsdyktig bukspyttkjertelkanser.

Country Status (16)

Country Link
US (3) US8318683B2 (no)
EP (1) EP1711188B1 (no)
JP (4) JP5235304B2 (no)
KR (2) KR101226631B1 (no)
CN (1) CN1917885A (no)
AU (1) AU2005213372B2 (no)
BR (1) BRPI0507463A (no)
CA (1) CA2554463C (no)
DK (1) DK1711188T3 (no)
ES (1) ES2389809T3 (no)
IL (1) IL177136A (no)
NO (1) NO336884B1 (no)
NZ (1) NZ549605A (no)
RU (1) RU2006132069A (no)
WO (1) WO2005076888A2 (no)
ZA (1) ZA200606456B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
EP1711188B1 (en) 2004-02-06 2012-06-06 Threshold Pharmaceuticals, Inc. Anti-cancer therapies
WO2006071955A2 (en) * 2004-12-23 2006-07-06 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
SI1896040T1 (sl) 2005-06-29 2012-12-31 Threshold Pharmaceuticals, Inc. Fosforamidatna alkilatorska predzdravila
BRPI0717998A2 (pt) * 2006-11-03 2013-12-03 Nerviano Medical Sciences Srl Método para administrar um composto antitumor.
WO2008083101A1 (en) 2006-12-26 2008-07-10 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
US8765690B2 (en) * 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
WO2010019396A1 (en) * 2008-08-13 2010-02-18 Threshold Pharmaceuticals, Inc. Administration of glufosfamide for the treatment of cancer
RU2555326C2 (ru) * 2009-01-16 2015-07-10 Риджел Фармасьютикалз, Инк. ИНГИБИТОРЫ Axl ДЛЯ ПРИМЕНЕНИЯ В КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ПРЕДОТВРАЩЕНИЯ, УСТРАНЕНИЯ ИЛИ ЛЕЧЕНИЯ МЕТАСТAЗИРУЮЩЕГО РАКА
TWI448295B (zh) 2011-11-15 2014-08-11 Univ Kaohsiung Medical 抗人類泌尿上皮癌之香桂超臨界萃取物、製備方法及用途
EP3430170B1 (en) 2016-03-16 2023-08-16 Dana-Farber Cancer Institute, Inc. Methods for genome characterization
CN110248664B (zh) * 2017-11-28 2023-03-03 深圳艾欣达伟医药科技有限公司 葡磷酰胺的抗癌医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489302A (en) * 1979-09-24 1984-12-18 Eventoff Franklin Neal Electronic pressure sensitive force transducer
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0184365B1 (en) * 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
DE3835772A1 (de) * 1988-10-20 1990-04-26 Deutsches Krebsforsch Tumorhemmende saccharid-konjugate
DE19524515A1 (de) * 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US7452538B2 (en) * 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
AU2003230750A1 (en) * 2002-03-29 2003-10-13 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
MXPA05007382A (es) * 2003-01-10 2005-11-23 Threshold Pharmaceuticals Inc Tratamiento de cancer con 2-desoxiglucosa.
WO2004081181A2 (en) 2003-03-07 2004-09-23 Threshold Pharmaceuticals, Inc. Method for determining susceptibility of tumor to treatment with anti-neoplastic agent
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
EP1711188B1 (en) 2004-02-06 2012-06-06 Threshold Pharmaceuticals, Inc. Anti-cancer therapies
WO2006071955A2 (en) 2004-12-23 2006-07-06 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
WO2006122227A1 (en) 2005-05-11 2006-11-16 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
JP2009509974A (ja) 2005-09-23 2009-03-12 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 抗癌治療

Also Published As

Publication number Publication date
JP2013064002A (ja) 2013-04-11
IL177136A0 (en) 2006-12-10
JP2007520562A (ja) 2007-07-26
US8318683B2 (en) 2012-11-27
US9205098B2 (en) 2015-12-08
NZ549605A (en) 2010-01-29
CN1917885A (zh) 2007-02-21
AU2005213372B2 (en) 2011-03-24
KR101226631B1 (ko) 2013-01-28
JP2017071625A (ja) 2017-04-13
DK1711188T3 (da) 2012-09-10
NO336884B1 (no) 2015-11-23
KR20120117943A (ko) 2012-10-24
ES2389809T3 (es) 2012-10-31
ZA200606456B (en) 2008-01-08
WO2005076888A3 (en) 2005-10-27
US20170157161A1 (en) 2017-06-08
WO2005076888A2 (en) 2005-08-25
RU2006132069A (ru) 2008-03-20
JP2018177808A (ja) 2018-11-15
AU2005213372A1 (en) 2005-08-25
EP1711188B1 (en) 2012-06-06
CA2554463A1 (en) 2005-08-25
CA2554463C (en) 2013-06-11
JP5235304B2 (ja) 2013-07-10
BRPI0507463A (pt) 2007-07-10
IL177136A (en) 2010-11-30
EP1711188A2 (en) 2006-10-18
US20130045944A1 (en) 2013-02-21
KR20060131869A (ko) 2006-12-20
US20090247480A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
NO20063987L (no) Anti-cancerterapier
NO20054988L (no) Preparater og metoder for behandling av cancer
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
CA2875824C (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
DK3248600T3 (da) Kombinationer og måder til administration af terapeutiske stoffer og kombinationsterapi
WO2007081879A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
ZA200709011B (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
MX2009011025A (es) Compuestos con actividad anticancer.
WO2008085229A3 (en) Cell-based therapies for treating liver disease
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
BRPI0506888A (pt) composições de suplemento lìquido compreendendo um ou mais medicamentos
MX2009012598A (es) Formas de dosis que comprenden vx-950 y su regimen de dosificacion.
BR112012011485A2 (pt) "composições e métodos para tratar náusea e vômito centralmente mediados".
NO20091191L (no) Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme
EP1765075A4 (en) PYRIMIDINES, IN PARTICULAR URIDINE, USED IN TREATMENTS ON PATIENTS WITH BIPOLAR DISORDERS
MX2007013056A (es) Metodo para tratar cancer ovarico avanzado con doxorrubicina atrapada en liposomas.
WO2009098464A3 (en) Use of g-rich oligonucleotides for treating neoplastic diseases
WO2012082821A3 (en) Melanoma treatments
WO2009138507A3 (en) Anti-cancer combination therapy
MX2009001433A (es) Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.
NO20092078L (no) Fremgangsmate for behandling av alkoholmisbruk, adiksjon og avhengighet
BRPI0810682A2 (pt) agente antitumoral em especial para o tratamento de tumores dérmicos, fármaco, kit compreendendo fármaco.